Position in NVS
as of Jun 30, 2026
· filed Jul 20, 2026
Position Value
$1,028,710
+$56,915 QoQ
Shares Held
6,564
+3.2% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#610
of 1,603 holders
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026GATEWAY INVESTMENT ADVISERS LLC holds $453,028,056 across 11 Drug Manufacturers - General names. NVS ranks #9 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
126,367 | $151,568,383 | |
| 2 | JNJ |
Johnson & Johnson
|
408,642 | $103,782,808 | |
| 3 | ABBV |
AbbVie Inc.
|
304,186 | $76,545,365 | |
| 4 | MRK |
Merck & Co., Inc.
|
433,052 | $55,647,182 | |
| 5 | AMGN |
Amgen Inc
|
117,268 | $42,465,088 | |
| 6 | BIIB |
Biogen Inc.
|
51,023 | $11,024,029 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
66,521 | $8,404,263 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
24,915 | $1,435,602 |
All Filings in NVS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,028,710 | 6,564 | Shares | Sole | 2026-07-20 | |
| 2026-03-31 | $971,795 | 6,362 | Shares | Sole | 2026-04-13 | |
| 2025-12-31 | $802,541 | 5,821 | Shares | Sole | 2026-02-03 | |
| 2025-09-30 | $739,688 | 5,768 | Shares | Sole | 2025-10-21 | |
| 2025-06-30 | $338,949 | 2,801 | Shares | Sole | 2025-07-09 | |
| 2025-03-31 | $294,530 | 2,642 | Shares | Sole | 2025-04-11 | |
| 2024-09-30 | $272,942 | 2,373 | Shares | Sole | 2024-10-10 | |
| 2024-06-30 | $252,629 | 2,373 | Shares | Sole | 2024-07-12 | |
| 2024-03-31 | $229,540 | 2,373 | Shares | Sole | 2024-04-12 | |
| No filing history on record for this holder in this stock. | ||||||